MIRM
HEALTHCAREMirum Pharmaceuticals Inc
$110.08+4.27 (+4.04%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving MIRM Today?
No stock-specific AI insight has been generated for MIRM yet. However, MIRM was mentioned in the following AI insights:
52-Week Range
$42.89$112.00
$110.08
Fundamentals
Market Cap$6.7B
P/E Ratio—
EPS$-0.47
Dividend Yield—
Dividend / Share—
ROE-0.1%
Profit Margin-0.0%
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding61.0M
MIRM News
20 articles- Mirum Pharmaceuticals (MIRM) Is Up 16.9% After Volixibat Phase 2b PSC Itch Data And Big Q1 Loss - Has The Bull Case Changed?Yahoo Finance·May 7, 2026
- Mirum's Q1 Earnings & Revenues Beat Estimates, 2026 View RaisedYahoo Finance·May 7, 2026
- Penn Capital Unloads 1.13 Million RealReal Shares Following Massive Stock Run-UpMotley Fool·May 7, 2026
- Mirum Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·May 7, 2026
- Mirum Pharmaceuticals, Inc. Q1 2026 Earnings Call SummaryMoby·May 7, 2026
- Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q1 EarningsYahoo Finance·May 6, 2026
- Mirum (MIRM) Q1 2026 Earnings Call TranscriptMotley Fool·May 6, 2026
- Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 6, 2026
- Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 6, 2026
- How The Mirum Pharmaceuticals (MIRM) Story Is Evolving With New Analyst Targets And Trial MilestonesYahoo Finance·May 5, 2026
- The $1 Billion-Plus Opportunity That Sent Mirum Pharma Catapulting To A RecordYahoo Finance·May 4, 2026
- Why This Biotech ETF — The IBD Stock Of The Day — Just Reentered Its Buy ZoneYahoo Finance·May 4, 2026
- Mirum Pharmaceuticals Says Volixibat Phase IIb VISTAS Hits Endpoint, Cuts PSC Itch vs PlaceboMarketbeat·May 4, 2026
- Mirum's Volixibat Meets Phase 2b Study Goal, Shows Significant Itch Reduction in PSCYahoo Finance·May 4, 2026
- Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing CholangitisYahoo Finance·May 4, 2026
- Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026Yahoo Finance·May 3, 2026
- Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026Yahoo Finance·Apr 29, 2026
- Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseYahoo Finance·Apr 29, 2026
- Biogen Inc. (BIIB) Tops Q1 Earnings and Revenue EstimatesYahoo Finance·Apr 29, 2026
- Assessing Mirum Pharmaceuticals (MIRM) Valuation After Strong Shareholder Returns And Rare Disease Pipeline ProgressYahoo Finance·Apr 29, 2026
All 20 articles loaded
Price Data
Open$0.00
Previous Close$105.81
Day High$0.00
Day Low$0.00
52 Week High$112.00
52 Week Low$42.89
52-Week Range
$42.89$112.00
$110.08
Fundamentals
Market Cap$6.7B
P/E Ratio—
EPS$-0.47
Dividend Yield—
Dividend / Share—
ROE-0.1%
Profit Margin-0.0%
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding61.0M
About Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of an advanced line of novel therapies for debilitating liver diseases. The company is headquartered in Foster City, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—